share_log

IRhythm Technologies Anticipates 2024 Revenue Above $587.5M; Expect Revenue For FY25 Of ~$675M-$685M

IRhythm Technologies Anticipates 2024 Revenue Above $587.5M; Expect Revenue For FY25 Of ~$675M-$685M

iRhythm Technologies預計2024年營業收入超過5.875億美元;預計2025財年的營業收入爲約67500萬.685萬美元
Benzinga ·  01/13 14:09

iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.

iRhythm Technologies, Inc.(納斯達克:IRTC)是一家領先的互聯網醫療公司,專注於創造可信的解決方案以檢測、預測和預防疾病,今天在第43屆摩根大通醫療保健會議上宣佈了初步的第四季度運營亮點和業務更新。

Recent Operational Highlights and Financial Outlook

近期運營亮點和財務展望

  • Anticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024
  • Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accounts
  • Launched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025
  • Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024
  • Five studies presented at the American Heart Association highlight Zio Monitor's high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns1
  • Expect revenue for the full year 2025 of approximately $675 million to $685 million
  • 預計2024年全年營業收入略高於2024年10月所提供的58750萬的先前指導區間高點
  • 2024年第四季度Zio監測儀和Zio At的新賬戶開設數量創紀錄,並且來自大型國家賬戶的成交量貢獻強勁
  • 在2024年第四季度推出了首批四個在Epic Aura上的醫療保健系統,2025年將在美國開始對Epic醫療系統進行廣泛商業推廣
  • 在2024年第四季度爲家庭註冊患者啓動了Zio監測儀的發貨
  • 在美國心臟協會展示的五項研究強調了Zio監測儀的高患者滿意度、參與度和與患者MyZio應用及數字工具的合規性、早期檢測心律失常對2型糖尿病和呼吸疾病的健康經濟影響,以及人工智能對睡眠和活動模式的洞察
  • 預計2025年全年營業收入約爲67500萬至68500萬

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 374

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。